WT1 is an inhibitor of SRPK1 phosphorylation; Denys Drash Syndrome patients have a mutation in WT1, resulting in no inhibition of SRPK1 and an increased VEGF-A165/VEGF-A165b ratio [29]. This evidence concerns the gene VEGFA and Denys-Drash syndrome.